Therapy protocols
How our clinical programs are designed, delivered, and medically overseen.
How a treatment is given.
Each Cellcolabs clinical program is built on decades of scientific research and clinical expertise. Mesenchymal stem cells are manufactured and administered through established medical routes, either intravenously or locally, in a controlled and medically supervised setting. The choice of treatment method is set out in the protocol.
In intravenous (IV) treatment, mesenchymal stem cells (MSCs) are delivered through an IV line, allowing them to circulate throughout the body and support systemic healing.
Administration:
IV infusion via a vein in the arm
Typical dose:
100 million MSCs
Eligibility:
Adults 25+, subject to medical assessment
Follow-up:
Video follow-ups at 1 and 6 months, with long-term monitoring
Price:
Starting from 27,500 USD
In intra-articular (IA) treatment, mesenchymal stem cells (MSCs) are injected directly into a joint, concentrating the treatment on a specific area.
Administration:
Ultrasound-guided injection into a joint
Typical dose:
50 million MSCs per joint
Eligibility:
Adults 18+
Follow-up:
Clinical follow-ups at 1, 3 and 6 months
Price:
Starting from 19,000 USD
Your treatment journey
Medical assessment
Each clinical program begins with an evaluation by the treating physician to determine eligibility and suitability within the applicable protocol.
Preparation and planning
Clinical and practical preparations are carried out in accordance with the relevant protocol and local clinical procedures.
Therapy delivery
Therapy is administered in a clinical setting by qualified medical professionals, using the route of administration defined in the protocol.
Monitoring and follow-up
Patients are monitored in line with protocol requirements, with follow-up procedures adapted to the clinical program.
Where the cells come from.
Donor selection
The mesenchymal stem cells (MSCs) used in our therapies are sourced from healthy bone marrow donors in Sweden and expanded under controlled laboratory conditions.
All donors are healthy volunteers aged 18–30 and undergo comprehensive health screening in accordance with protocols certified by the Swedish Medical Authorities. Only thoroughly verified donor material enters our GMP-certified manufacturing process.
Cell source
Bone marrow–derived MSCs are the most extensively studied cell source in clinical research, with a long history of medical use. For this reason, Cellcolabs exclusively sources MSCs from bone marrow.
Manufactured in Sweden.Delivered worldwide.
Every Cellcolabs Clinical dose begins in our EU-GMP certified facility in Sweden and is safeguarded through GDP-regulated transport. Across all clinics, physicians follow one unified global protocol. The result is consistent quality and clinically responsible care wherever treatment is delivered.
Frequently asked questions.
Eligibility is determined by the study doctor based on the clinical trial’s inclusion and exclusion criteria. You will be medically assessed before treatment to verify safety and suitability.
Treatment can be given either as a slow intravenous (IV) infusion or as a local injection under ultrasound guidance directly into a joint or ligament, depending on the medical indication definend in the clinical trial protocol.
The mesenchymal stem cells (MSCs) used by Cellcolabs Clinical are sourced from bone marrow donated by healthy individuals aged 18–30. The cells are rigorously screened and cultured in a GMP-certified facility in Stockholm, Sweden
Yes. Donors undergo rigorous health checks and the cells are produced, controlled and quality released under strict manufacturing standards (GMP) before being used in clinical trials, ensuring quality and safety.
Treatments take place at the clinical trial sites listed on the website. Participants are assessed, treated, and observed onsite; after the cellular administration, you remain at the clinic for observation as part of the protocol.
Treatments take place at the clinical trial sites listed on the website. Participants are assessed, treated, and observed onsite; after the cellular administration, you remain at the clinic for observation as part of the protocol.